1. Scrip
  3. >>China

Watch Out GSK! China’s Homegrown Shingles Vaccine Set To Soar

Other Competitors Looming

 
• By Dexter Jie Yan

Although the domestic developer did not provide sales figures for 2023, a new homegrown shingles vaccine in China is poised to eat into the market share of GSK’s Shingrix in the country.

herpes zoster vaccine
China's herpes zoster vaccine market set for more entrants • Source: Shutterstock

China’s first homegrown vaccine for herpes zoster (shingles), Ganwei, developed by Changchun BCHT Biotechnology Co. (BCHT), had a strong commercial launch in 2023, setting the stage for a showdown with GSK plc’s global blockbuster Shingrix in China’s rapidly growing preventive care market.

BCHT said in a new forecast that its total 2023 revenue is expected to jump by 64-75% versus the previous year, to between CNY1.8bn ($244.6) and CNY1.9bn

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia